Article Text
PDFCorrection
Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Statistics from Altmetric.com
Hall EM, Yin DE, Goyal RK, et al. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. J ImmunoTher Cancer 2021;9:e001225. doi: 10.1136/jitc-2020-001225
This article has been corrected since it first published. The provenance and peer review statement has been added.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.